Nurix Therapeutics (NASDAQ:NRIX – Get Free Report) and BioLineRx (NASDAQ:BLRX – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, risk, valuation and profitability.
Profitability
This table compares Nurix Therapeutics and BioLineRx’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nurix Therapeutics | 42.01% | 49.34% | 38.61% |
| BioLineRx | -502.08% | -34.80% | -18.27% |
Analyst Ratings
This is a breakdown of current recommendations for Nurix Therapeutics and BioLineRx, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nurix Therapeutics | 1 | 0 | 14 | 0 | 2.87 |
| BioLineRx | 1 | 0 | 0 | 0 | 1.00 |
Nurix Therapeutics presently has a consensus target price of $34.43, indicating a potential upside of 122.41%. Given Nurix Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Nurix Therapeutics is more favorable than BioLineRx.
Insider & Institutional Ownership
1.6% of BioLineRx shares are held by institutional investors. 6.7% of Nurix Therapeutics shares are held by insiders. Comparatively, 1.1% of BioLineRx shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Volatility and Risk
Nurix Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the S&P 500. Comparatively, BioLineRx has a beta of 1.64, indicating that its share price is 64% more volatile than the S&P 500.
Valuation and Earnings
This table compares Nurix Therapeutics and BioLineRx”s top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nurix Therapeutics | $83.98 million | 20.14 | -$264.46 million | $2.31 | 6.70 |
| BioLineRx | $1.18 million | 5.32 | -$1.17 million | ($1.69) | -0.75 |
BioLineRx has lower revenue, but higher earnings than Nurix Therapeutics. BioLineRx is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Nurix Therapeutics beats BioLineRx on 12 of the 14 factors compared between the two stocks.
About Nurix Therapeutics
Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in San Francisco, California. Founded in 2009, it develops medicines that aim to treat cancer and other diseases by changing the levels of specific proteins inside cells. The company’s technology focuses on protein degradation, using the cell’s natural protein-disposal system to remove disease-related proteins. Nurix also researches ways to regulate protein activity through ubiquitin signaling, a process that helps control how proteins function and are broken down.
About BioLineRx
BioLineRx Ltd. is an Israel-based biopharmaceutical company that develops therapies for cancer and other serious diseases. Founded in 2003, the company advances drug candidates through clinical development and works with commercial and development partners. Its lead product, motixafortide, is marketed in the United States as Aphexda. The FDA approved Aphexda, in combination with filgrastim, to mobilize hematopoietic stem cells for collection in adults with multiple myeloma who are preparing for autologous transplantation.
Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
